Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes

Phase 1/2 Completed 43 enrolled The Affiliated Hospital of the Chinese Academy of Military Medical Sciences The Second Artillery General Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate whether infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC) combining decitabine and cytarabine chemotherapy can improve outcomes in myelodysplastic syndromes (MDS) patients.

Timeline

Start: 2009-09
Primary completion: 2013-10
Completion: 2015-12

Publications

Background Guo M, Hu KX, Yu CL, Sun QY, Qiao JH, Wang DH, Liu GX, Sun WJ, Wei L, Sun XD, Huang YJ, Qiao JX, Dong Z, Ai HS. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011 Jan 20;117(3):936-41. doi: 10.1182/blood-2010-06-288506. Epub 2010 Oct 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Microtransplantation	Cell therapy	—	—

Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes

Summary

Timeline

Publications

Drugs

Indications